Anna Unseld

Dual Glucagon and GLP ‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Elif Ilhan Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla et autres

AIMS: This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. MATERIALS AND METHODS: Trial 1404-0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, …

au, de (code pays fourni par la source)

Survodutide Once Weekly for the Treatment of Adults with Obesity

Carel W. le Roux, Sean Wharton, E Startseva, Isabel M. Kloer et autres

BACKGROUND: Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain. Survodutide, an investigational glucagon receptor-GLP-1 receptor dual agonist, led to substantial weight reduction in a phase 2 trial …

ie, gb, ca, de, us, pl, au, cn, jp, fi, se, nl, be (code pays fourni par la source)

Author response for "Dual glucagon and GLP-1 receptor agonist survodutide improves biomarkers of beta-cell function and insulin sensitivity in people with type 2 diabetes or living with overweight / obesity"

Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez et autres

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist

Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas, Elena Startseva et autres

AIM: . MATERIALS AND METHODS: , without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance). Participants were categorized according to sex and baseline BMI. Data …

ie, de (code pays fourni par la source)

Author response for "Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist"

Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas, Elena Startseva et autres

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial

Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas, Elif Ilhan Ekinci et autres

ie, au, de (code pays fourni par la source)

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2)

Sean Wharton, Carel Wynand le Roux, Mikhail Kosiborod, Elke Platz et autres

Abstract Objective The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon‐like peptide‐1 receptor dual agonist for the treatment of obesity with or without type 2 …

ca, ie, us, de (code pays fourni par la source)

Survodutide for the Treatment of Obesity

Mikhail Kosiborod, Elke Platz, Sean Wharton, Carel Wynand le Roux et autres

Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, …

us, ca, ie, de (code pays fourni par la source)

Author response for "Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial"

Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas, Elif Ilhan Ekinci et autres

6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight/Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial

Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas, Elena Startseva et autres

Abstract Disclosure: C.W. Le Roux: Consulting Fee; Self; Boehringer Ingelheim, Novo Nordisk, GI Dynamics, Herbalife, Johnson & Johnson, Eli Lilly, Keyron. O. Steen: Consulting Fee; Self; Eli Lilly & Company, Novo Nordisk, Sanofi. Grant Recipient; Self; Alnylam, Anji, AstraZeneca, Boehringer Ingelheim, Eli …

ie, be, de, cn, in (code pays fourni par la source)

Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial

Carel Wynand le Roux, O. Van de Steen, Kayli J. Lucas, Elif Ilhan Ekinci et autres

Abstract Background Obesity increases the risk of cardiovascular (CV) disease and contributes to CV risk factors, such as hypertension (HTN) and dyslipidaemia. Survodutide is a GCGR/GLP-1R dual agonist in clinical development for obesity. In a phase 2 clinical trial in individuals with …

ie, be, au, cn, de, tw (code pays fourni par la source)

Author response for "Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial"

Carel Wynand le Roux, Oren Steen, Kathryn Jean Lucas, Elif Ilhan Ekinci et autres